Please login to the form below

Not currently logged in
Email:
Password:

Symphogen

This page shows the latest Symphogen news and features for those working in and with pharma, biotech and healthcare.

Merck gets first approval for MET inhibitor tepotinib in Japan

Merck gets first approval for MET inhibitor tepotinib in Japan

Meanwhile Symphogen has a MET-targeting antibody combination – codenamed Sym015 – in trials for METex14-positive solid tumours, although it is in the midst of a strategic review of its operations.

Latest news

  • Baxalta makes $1.7bn play for slice of CAR-T market Baxalta makes $1.7bn play for slice of CAR-T market

    The deal comes a few weeks after Baxalta agreed a deal with Symphogen worth up to $1.6bn to develop a series of novel checkpoint inhibitor drugs, making a bold foray

  • Baxalta agrees to $32bn Shire takeover Baxalta agrees to $32bn Shire takeover

    Meanwhile, eyebrows were raised earlier this month when Baxalta signed a $1.6bn deal with Symphogen in oncology - which is not a major focus of either of the merging companies although

  • Baxalta inks $1.6bn immuno-oncology deal with Symphogen Baxalta inks $1.6bn immuno-oncology deal with Symphogen

    Baxalta is paying $175m upfront for an option on a series of six checkpoint inhibitors in early-stage development at privately-held Danish biopharma Symphogen, along with milestone payments worth up ... Copenhagen-based Symphogen said the first of the

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    Only days before this, Baxalta had announced the investment of $175m upfront in a strategic collaboration with Symphogen taking the company into the ever popular field of oncology (headline deal value ... upfront. 1, 900. Symphogen/ Baxalta.

  • Pharma deals during September 2012 Pharma deals during September 2012

    In its search for a follow-on to Erbitux, Merck KGaA has taken an exclusive worldwide licence to Symphogen's Sym004, currently in phase I/II trials, for the treatment of ... 665. Symphogen / Merck KGaA. Product licence. Sym004 for advanced KRAS; a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....